ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

After Aggressive Budgetary Trimming, At $33 Million NCI’s caBIG Remains Big

December 2, 2011

Royston Retires At Kimmel; Cancer Care Gives Awards.

June 22, 2001

Ontak Approved For Lymphoma

October 31, 2008

RFPs Go Out To Cooperative Groups for Community Programs

April 9, 1976

Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.

July 9, 2004

Consensus Growing On Prevention Strategies: Higginson

August 14, 1981